Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DHAP and Primaquine for Malaria Mass Drug Administration in Ghana
NCT07389057Recruiting
- Sponsor
- Noguchi Memorial Institute for Medical Research
- Start
- Nov 2023
- Primary completion
- Nov 2026
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of dihydroartemisinin + piperaquine and primaquine in malaria (3 arms), sponsored by Noguchi Memorial Institute for Medical Research. Primary endpoint: Effect of DHAP and DHAP+PQ on the prevalence of malaria infection following MDA at 24 months. Started Nov 2023; status: recruiting.
02
Drugs
dihydroartemisinin + piperaquineprimaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07389057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07389057.